Sf9

Avirmax Inc. to Make Scientific Presentations at ASGCT in Baltimore

Retrieved on: 
Martedì, Aprile 16, 2024
Rabbit, AMD, Mouse, PCV, Tropism, Cell, AAV, Sf9, Gene, Society, Sf9 (cells), Molecular Therapy, HEK293, CGMP, Vaccine

HAYWARD, Calif., April 15, 2024 /PRNewswire/ -- Avirmax Inc., will make two scientific presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore between May 7th and 11th, 2024.

Key Points: 
  • HAYWARD, Calif., April 15, 2024 /PRNewswire/ -- Avirmax Inc., will make two scientific presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore between May 7th and 11th, 2024.
  • In addition, Avirmax will have an exhibitor booth #818 to showcase the latest progress and data package.
  • ASGCT is the largest international society dedicated to understanding, development, and application of gene and cell therapy.
  • Avirmax Biopharma has completed cGMP manufacturing of ABI-110 using VSafTM rAAV Production Platform with Sf-rhabdovirus free Sf9 cells and presently prepares regulatory submission for clinical investigations.

Avirmax Biopharma Inc. to Present at the 2024 ARVO Annual Meeting in Seattle

Retrieved on: 
Lunedì, Aprile 1, 2024
Research, Neuroprotection, Sf9, Glaucoma, ARVO, HEK293, HEK 293 cells

HAYWARD, Calif., April 1, 2024 /PRNewswire/ -- Avirmax Biopharma Inc., will make three scientific presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle between May 5th and 9th, 2024.

Key Points: 
  • HAYWARD, Calif., April 1, 2024 /PRNewswire/ -- Avirmax Biopharma Inc., will make three scientific presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle between May 5th and 9th, 2024.
  • ARVO is the largest international society dedicated to ophthalmology and vision-related topics.
  • Dr. Shengjiang Liu, Ph.D. Chief Executive and Scientific Officer, is invited to present "Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells", at the 2024 ARVO Symposium on "Developing gene therapy for glaucoma neuroprotection: Opportunities and challenges", May 9, 8 – 10 am.
  • In addition to the invited talk, there will be two more scientific presentations from Avirmax Biopharma and an exhibitor booth #1604 to showcase the latest progress and data package:

EXPRESSION SYSTEMS LAUNCHES RHABDOVIRUS-FREE CELL LINE FOR DEVELOPMENT OF ADVANCED THERAPIES

Retrieved on: 
Mercoledì, Giugno 28, 2023
Immortalised cell line, GMP, ANGUS, Sf9, Gene, Cell bank, Research, AAV, Zenith Contract Services, Documentation, Cell, ESF, VLP, Growth, A-DNA, Vaccine

BUFFALO GROVE, Ill. and DAVIS, Calif., June 28, 2023 /PRNewswire/ -- Expression Systems, an ANGUS company, and a leading global provider of specialty cell culture media formulations, cell lines, and contract services for the baculovirus expression platform, today announced early-access availability of its new rhabdovirus-free cell line for manufacturing advanced therapies.  

Key Points: 
  • BUFFALO GROVE, Ill. and DAVIS, Calif., June 28, 2023 /PRNewswire/ -- Expression Systems, an ANGUS company, and a leading global provider of specialty cell culture media formulations, cell lines, and contract services for the baculovirus expression platform, today announced early-access availability of its new rhabdovirus-free cell line for manufacturing advanced therapies.
  • The Sf9 RV-Free Insect Cell Line is a proven rhabdovirus-negative Sf9 cell line grown in suspension culture and adapted for optimized growth in Expression Systems' new ESF AdvanCD Chemically Defined Insect Cell Culture Medium.
  • "We are thrilled with the exceptional growth characteristics of Expression Systems' Sf9 RV-Free Insect Cells with our new ESF AdvanCD Chemically Defined Insect Cell Culture Medium," said Thera Mulvania, President, Expression Systems.
  • The Sf9 RV-Free Cell Line is available exclusively from Expression Systems for research use only under a Limited Use Label License ("LULL").

Avirmax CMC Inc. Launches AAV Production with Sf Rhabdovirus-free Cell Lines (Sf-RVF™)

Retrieved on: 
Giovedì, Marzo 23, 2023
Immortalised cell line, Vaccine, Sf9, SF, Research, RNA, CDMO, Rita Raave, ACI, A-DNA, DVM

However, Sf9 cell lines persistently carries Sf rhabdovirus (Sf-RV), an enveloped, negative sense and single stranded RNA (-ssRNA) virus.

Key Points: 
  • However, Sf9 cell lines persistently carries Sf rhabdovirus (Sf-RV), an enveloped, negative sense and single stranded RNA (-ssRNA) virus.
  • When using serum-free suspension culture, Avirmax CMC's Sf-RVF™ cell lines have been shown to be comparable with respect to rAAV yields and quality, relative to rAAV produced using Sf-RV parental cell lines.
  • Avirmax CMC Inc. is now using the Sf-RVF™ cell lines in rAAV manufacturing for research and clinical development purposes.
  • Avirmax CMC Inc. is also expanding the Sf-RVF™ cell lines to the production of other modalities including vaccines and protein drugs.

Avirmax CMC Inc. Received License for cGMP Gene Therapy Vector Production by the California Department of Public Health

Retrieved on: 
Lunedì, Ottobre 31, 2022
Bayer, HEK293, AAV, Founder CEO, CDMO, California Department, Knowledge, CEO, Sf9, Contract manufacturing organization, CGMP, BHK, Public health, Technology, Drug development, SUB, A-DNA, DNA, DVM, Rita Raave, Therapy, CHO, Vaccine, Fine chemical, San Francisco Bay Area, Genentech

The facility has received cGMP license approval by the California Department of Public Health (CDPH)-Food & Drug Branch, for the production of rAAV drug products for use in clinical investigations.

Key Points: 
  • The facility has received cGMP license approval by the California Department of Public Health (CDPH)-Food & Drug Branch, for the production of rAAV drug products for use in clinical investigations.
  • The new cGMP facility will support us to deliver high yield and quality vectors efficiently, timely and cost effectively
    The new 20,000 sq.ft.
  • Production scales at 50L, 200L and 1000L, are available to customers depending on their clinical trial size and dose requirements.
  • With our new facility, Avirmax CMC Inc. is able to deliver high yield and quality vectors efficiently, timely and cost effectively.

Novavax’ Preclinical NanoFlu Data Published in Vaccines; Details Structural Basis for Broadly Neutralizing Immunity

Retrieved on: 
Martedì, Febbraio 25, 2020
Medical specialties, RTT, Medicine, Vaccines, Microbiology, Viral structural proteins, Novavax, Influenza vaccine, Vaccine, Hemagglutinin, Influenza, Sf9

NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system.

Key Points: 
  • NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system.
  • NanoFlu uses HA amino acid protein sequences that are the same as the recommended wild-type circulating virus HA sequences.
  • Top-line data from Novavax ongoing Phase 3 clinical trial of NanoFlu is expected late in the first quarter of 2020.
  • Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products, including those regarding the potential for NanoFlu to offer broadly protective immunity and improved vaccine efficacy, are forward-looking statements.

Novavax Granted Fast Track Designation for NanoFlu in Older Adults

Retrieved on: 
Mercoledì, Gennaio 15, 2020
Medical specialties, Medicine, Vaccination, RTT, Vaccines, Influenza vaccine, Influenza, Vaccine, Immunogenicity, Novavax, Sf9, H5N1 clinical trials

The ongoing Phase 3 clinical trial is intended to evaluate the immunogenicity and safety of NanoFlu compared to the quadrivalent formulation of Fluzone.

Key Points: 
  • The ongoing Phase 3 clinical trial is intended to evaluate the immunogenicity and safety of NanoFlu compared to the quadrivalent formulation of Fluzone.
  • NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system.
  • Positive top-line results of a Phase 2 clinical trial of NanoFlu in older adults released in January 2019 showed that NanoFlu induced improved immune responses when compared to the best-selling flu vaccine in the older adult market.
  • Priority review (six-month review versus standard 10-month review) is an additional benefit that may potentially be availablefor NanoFlu as part of the Fast Track designation.